NO20054070L - 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. - Google Patents

4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.

Info

Publication number
NO20054070L
NO20054070L NO20054070A NO20054070A NO20054070L NO 20054070 L NO20054070 L NO 20054070L NO 20054070 A NO20054070 A NO 20054070A NO 20054070 A NO20054070 A NO 20054070A NO 20054070 L NO20054070 L NO 20054070L
Authority
NO
Norway
Prior art keywords
quinole
carbonitriles
methoxyphenyl
dichloro
alkoxy
Prior art date
Application number
NO20054070A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054070D0 (no
Inventor
Margaret Maria Zaleska
Diane Harris Boschelli
Frank Charles Boschelli
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054070(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054070D0 publication Critical patent/NO20054070D0/no
Publication of NO20054070L publication Critical patent/NO20054070L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054070A 2003-02-21 2005-09-01 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. NO20054070L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21
PCT/US2004/004904 WO2004075898A1 (en) 2003-02-21 2004-02-19 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (2)

Publication Number Publication Date
NO20054070D0 NO20054070D0 (no) 2005-09-01
NO20054070L true NO20054070L (no) 2005-11-14

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054070A NO20054070L (no) 2003-02-21 2005-09-01 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.

Country Status (19)

Country Link
US (1) US20040229880A1 (enExample)
EP (1) EP1594502A1 (enExample)
JP (1) JP2006522023A (enExample)
KR (1) KR20050102133A (enExample)
CN (1) CN1750824A (enExample)
AR (1) AR043253A1 (enExample)
AU (1) AU2004216235A1 (enExample)
BR (1) BRPI0407441A (enExample)
CA (1) CA2516418A1 (enExample)
CO (1) CO5640114A2 (enExample)
CR (1) CR7931A (enExample)
EC (1) ECSP055972A (enExample)
MX (1) MXPA05008706A (enExample)
NO (1) NO20054070L (enExample)
RU (1) RU2005129333A (enExample)
TW (1) TW200423938A (enExample)
UA (1) UA80472C2 (enExample)
WO (1) WO2004075898A1 (enExample)
ZA (1) ZA200506621B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
RU2007111704A (ru) * 2004-10-22 2008-11-27 Вайет (Us) 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения
MX2008000384A (es) * 2005-07-01 2008-03-07 Wyeth Corp Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
MX342879B (es) 2010-07-30 2016-10-14 Oncotherapy Science Inc * Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
IN2014CH00840A (enExample) 2014-02-20 2015-09-18 Apotex Inc
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
KR20180096621A (ko) 2015-12-18 2018-08-29 이그니타, 인코포레이티드 암의 치료용 조합물
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20060167021A1 (en) * 2002-10-04 2006-07-27 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
WO2004075898A1 (en) 2004-09-10
TW200423938A (en) 2004-11-16
US20040229880A1 (en) 2004-11-18
NO20054070D0 (no) 2005-09-01
MXPA05008706A (es) 2005-10-05
KR20050102133A (ko) 2005-10-25
RU2005129333A (ru) 2006-01-27
CA2516418A1 (en) 2004-09-10
CO5640114A2 (es) 2006-05-31
AR043253A1 (es) 2005-07-20
JP2006522023A (ja) 2006-09-28
ZA200506621B (en) 2008-02-27
ECSP055972A (es) 2006-01-16
BRPI0407441A (pt) 2006-01-31
AU2004216235A1 (en) 2004-09-10
UA80472C2 (en) 2007-09-25
CR7931A (es) 2006-02-07
CN1750824A (zh) 2006-03-22
EP1594502A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
NO20054070L (no) 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
NO991700L (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
JO2282B1 (en) Oxazole derivatives
WO2008108386A1 (ja) 医薬組成物
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
WO2008114819A1 (ja) 新規アデニン化合物
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
EA200600990A1 (ru) Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
UA66864C2 (uk) Похідні сечовини, фармацевтична композиція і спосіб лікування або профілактики запальних, аутоімунних або респіраторних захворювань
DE69529418D1 (de) Cyclopropachromencarbonsäure derivate
ATE501141T1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
CA2336412A1 (en) Medicament for treatment of diabetes
WO2006113552A8 (en) Cyanoarylamines
NO20062255L (no) 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
TW200727893A (en) Methods for treating sexual dysfunction
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
CA2441309A1 (en) Biguanide derivatives
NO20071708L (no) 4((2,4-diklor-5-metoksyfenyl) amino)-6-alkoksy-7-etynyl-3-kinolinkarbonitriler for behandling av ischemisk skade.
TW200745033A (en) Oxindole derivative as feeding control agent
PL353494A1 (en) Novel a-500359 derivatives
TW200612970A (en) Biotinylated hexadecasaccharides, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application